71.1 F
Fort Worth
Friday, October 23, 2020
Health Care Fort Worth- and Paris-based eye treatment startup raises $30M for further development

Fort Worth- and Paris-based eye treatment startup raises $30M for further development

Other News

A look at big issues on Supreme Court’s agenda

Some of the issues either already on the Supreme Court's docket when it begins its new session or likely to be before...

Wall Street posts solid gains after surge in corporate deals

By ALEX VEIGA and DAMIAN J. TROISE AP Business Writers Wall Street kicked off the week with a broad...

Tarrant County ranks low in work-from-home study by NAR

North Texas ranks pretty high in the “Work from Home” category, according to a just-released study by the National Association of Realtors....

Commentary: Universities and COVID-19: Charting turbulent times

Ray Perryman As the COVID-19 pandemic emerged this spring, college campuses across the United States swiftly sent students...

Biotech startup Eyevensys, based in Paris and Fort Worth, has raised $30 million in Series B funding.

Eyevensys will use the funding to further its development of non-viral gene therapies for retinal and other ophthalmic diseases.

The startup has a groundbreaking technology that allows the delivery of DNA plasmids encoding therapeutic proteins into the ciliary muscle through an electroporation system.

The company said its technology can turn the eye into a biofactory, allowing the ciliary muscle to express and secrete the therapeutic protein to the back of the eye at therapeutic levels for a duration of greater than 6 months.

“This funding will assist the further development of our technology and position Eyevensys as an innovator in the field of ophthalmology,” Eyevensys CEO Patricia Zilliox said.

Zilliox once led clinical development at Fort Worth’s Alcon Laboratories. She also worked for Alcon in Paris, where she oversaw its European ophthalmology clinical trials. She joined Eyevensys in 2018.

Eyevenesys recently opened a subsidiary in Fort Worth, where all U.S. operations are managed.

The company’s lead product, EYS606, combines Eyevensys’ proprietary Electrotransfection System to treat patients with chronic non-infectious uveitis. EYS606 is currently in phase I/II clinical trial in the EU and has been granted an Orphan drug designation.

A Phase 2 trial – Electro Study – will be conducted in the U.S. within the next couple of months, the company said.

“As we launch the Electro Study, our first U.S. clinical trial, Eyevensys will also have an opportunity to connect with ophthalmology opinion leaders in the U.S. to gain further exposure for our groundbreaking technology platform,” Zilliox said.

The company is funded by the Boehringer Ingelheim Venture Fund, Pureos Bioventures, Bpifrance through the Innobio Fund, CapDecisif, Inserm Transfert Initiative, Pontifax and the Global Health Sciences Fund.

The latest round of funding was also led by five of its existing investors. New investors in the round included the Global Health Sciences Fund [Quark Venture LP and GF Securities] and Pureos Bioventures.

This will also move the company one step closer to providing a more effective and convenient treatment approach to ease the burden of managing patients with chronic ocular conditions.”

Latest News

FDA approves first COVID-19 drug: antiviral remdesivir

By MARILYNN MARCHIONE AP Chief Medical WriterU.S. regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given...

Medical City Healthcare to Host “Crush the Crisis” Drug Take Back Day Oct. 24

Medical City Healthcare hospitals are hosting a drug take back event to raise awareness about the dangers of...

Tarrant County reports 2 COVID deaths

Tarrant County Public Health on Thursday, Oct. 22 reported two COVID-19 deaths. The deceased include a man from Arlington in his 80s...

Texas reports most active COVID-19 cases since summer peak

AUSTIN, Texas (AP) — The second coronavirus wave in Texas continued with more active cases than at any time since the summertime...

Tarrant County reports 1 COVID death

Tarrant County Public Health on Wednesday, Oct. 21 reported one COVID-19 death. The deceased was a man from Haltom City in his...